Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 9/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561 | 0.79 | CYP3A4 (0.53) | ALDH1A1KDM4EMAPK1SMN1; SMN2CYP3A4 | |
| SCHEMBL52405 | 0.78 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL29366129 | 0.78 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL9825588 | 0.77 | CYP3A4 (0.46) | ALDH1A1KDM4EMAPK1SMN1; SMN2CYP3A4 | |
| Iodide SCHEMBL5967814 | 0.75 | ALDH1A1 (0.94) | ALDH1A1KDM4EMAPK1SMN1; SMN2CYP1A2 | |
| Isopimpinellin SCHEMBL498907 | 0.73 | CYP3A4 (1.00) | ALDH1A1KDM4EMAPK1SMN1; SMN2CYP3A4 | |
| Isopimpinellin SCHEMBL29568822 | 0.73 | CYP3A4 (1.00) | ALDH1A1KDM4EMAPK1SMN1; SMN2CYP3A4 | |
| SCHEMBL12494527 | 0.72 | KCNA2 (0.42) | ALDH1A1KDM4ECYP3A4HPGDCYP1A1 | |
| SCHEMBL11539828 | 0.71 | KCNA3 (0.60) | ALDH1A1KDM4EMAPK1CYP3A4HPGD | |
| SCHEMBL30096399 | 0.71 | CYP3A4 (0.68) | ALDH1A1KDM4EMAPK1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109206390-B | Furanaphthoquinone-based sulfoximine derivative and application thereof in manufacturing STAT3 inhibitor | 北京大学 | 2021-04-27 | — | — | CN | disclosed |
| CN-109206390-A | Sulphoxide imine derivative based on furans naphthoquinones and its purposes in manufacture STAT3 inhibitor | 北京大学 | 2019-01-15 | — | — | CN | disclosed |
| CN-103153975-B | Novel naphthoquinones for use in the treatment of disease | Hangzhou Yier Biological Technology Co.,Ltd. (CN) | 2016-01-20 | — | — | CN | disclosed |
| US-9150530-B2 | Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2015-10-06 | — | — | US | disclosed |
| US-8871802-B2 | Naphthoquinones for disease therapies | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2014-10-28 | — | — | US | disclosed |
| EP-2681203-A1 | NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. (CN) | 2014-01-08 | — | — | EP | disclosed |
| US-20130345176-A1 | NOVEL ESTERS OF 4, 9-DIHYDROXY-NAPHTHO [2, 3-b] FURANS FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2013-12-26 | — | — | US | disclosed |
| CN-103402993-A | Novel esters of 4, 9-dihydroxy-naphtho [2,3-b ] furans for the treatment of diseases | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO LTD | 2013-11-20 | — | — | CN | disclosed |
| US-20130150437-A1 | NAPHTHOQUINONES FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2013-06-13 | — | — | US | disclosed |
| CN-103153975-A | Novel naphthoquinones for use in the treatment of disease | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO LTD | 2013-06-12 | — | — | CN | disclosed |
| WO-2012119265-A1 | NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012024818-A1 | NOVEL ANPHTHOQUINONES FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345176-A1 | NOVEL ESTERS OF 4, 9-DIHYDROXY-NAPHTHO [2, 3-b] FURANS FOR DISEASE THERAPIES | CYP46A1, HSD3B2, HSD3B1 | ALDH1A1 114/4885KDM4E 649/4885MAPK1 4263/4885 |
| US-20130150437-A1 | NAPHTHOQUINONES FOR DISEASE THERAPIES | NQO1, NME2, CYP27B1 | ALDH1A1 282/4885KDM4E 2313/4885MAPK1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.